{"id":"high-dose-anthracycline","safety":{"commonSideEffects":[{"rate":"null","effect":"Cardiotoxicity"},{"rate":"null","effect":"Myelosuppression"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anthracyclines work by intercalating DNA strands, which prevents the enzyme topoisomerase II from unwinding DNA during replication. This leads to DNA damage and ultimately cell death.","oneSentence":"anthracyclines intercalate DNA strands, inhibiting topoisomerase II","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:13.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute Myeloid Leukemia"},{"name":"Breast Cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT06332508","phase":"PHASE1","title":"Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2022-12-30","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT07425782","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine for Consolidation Therapy in AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax","enrollment":216},{"nctId":"NCT00003042","phase":"PHASE2","title":"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-05-30","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT00352534","phase":"PHASE3","title":"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2006-11-06","conditions":"Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor","enrollment":808},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT03033914","phase":"PHASE1, PHASE2","title":"A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-25","conditions":"Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT01516567","phase":"PHASE2","title":"Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2012-04-01","conditions":"Primary Mediastinal Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT05342584","phase":"PHASE1","title":"Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-05-25","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":99},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT06835049","phase":"PHASE2","title":"Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2025-10-27","conditions":"Sarcoma,Soft Tissue","enrollment":24},{"nctId":"NCT01746238","phase":"PHASE1","title":"Bevacizumab/Doxorubicin/Radiation for Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2013-03","conditions":"Sarcoma","enrollment":14},{"nctId":"NCT04659616","phase":"PHASE1","title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-01-14","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03330821","phase":"PHASE1, PHASE2","title":"Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-04-18","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm","enrollment":1645},{"nctId":"NCT07232134","phase":"PHASE3","title":"The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-07-24","conditions":"AML (Acute Myelogenous Leukemia), Down Syndrome (DS)","enrollment":100},{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT04817241","phase":"PHASE1, PHASE2","title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-10","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT03900949","phase":"PHASE1","title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Uma Borate","startDate":"2019-03-13","conditions":"Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT06687772","phase":"PHASE2","title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT04443348","phase":"PHASE2","title":"Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura M. Spring, MD","startDate":"2020-12-16","conditions":"Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)","enrollment":120},{"nctId":"NCT01760226","phase":"EARLY_PHASE1","title":"Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":"Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma","enrollment":4},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":"B-cell Lymphoma, Burkitt Lymphoma","enrollment":11},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT04243616","phase":"PHASE2","title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-03-05","conditions":"Invasive Breast Cancer","enrollment":36},{"nctId":"NCT00186888","phase":"PHASE3","title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04-07","conditions":"Retinoblastoma, Retinal Neoplasm","enrollment":107},{"nctId":"NCT06429098","phase":"PHASE2","title":"Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":"Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome","enrollment":280},{"nctId":"NCT01275677","phase":"PHASE3","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma","enrollment":3270},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT03742258","phase":"PHASE1","title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-03-13","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":12},{"nctId":"NCT03724084","phase":"PHASE1, PHASE2","title":"Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-10","conditions":"Acute Myeloid Leukemia","enrollment":6},{"nctId":"NCT03836209","phase":"PHASE2","title":"Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2019-12-06","conditions":"Acute Myeloid Leukemia","enrollment":181},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT03995147","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-08-29","conditions":"B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell","enrollment":51},{"nctId":"NCT06730542","phase":"PHASE1","title":"Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2025-04-17","conditions":"CNS Lymphoma","enrollment":20},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT03572764","phase":"PHASE1","title":"CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-12-14","conditions":"Myelodysplastic Syndromes","enrollment":20},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT01190930","phase":"PHASE3","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-08-09","conditions":"Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma","enrollment":9350},{"nctId":"NCT04296175","phase":"PHASE3","title":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-03-05","conditions":"Triple-negative Breast Cancer","enrollment":808},{"nctId":"NCT02038777","phase":"PHASE1","title":"A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-25","conditions":"Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT04778397","phase":"PHASE3","title":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-07-01","conditions":"Acute Myeloid Leukemia","enrollment":258},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT04109066","phase":"PHASE3","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":521},{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT04996004","phase":"PHASE2","title":"A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-06-22","conditions":"Leiomyosarcoma","enrollment":76},{"nctId":"NCT02889523","phase":"PHASE1, PHASE2","title":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-10","conditions":"Lymphoma, DLBCL, Follicular Lymphoma","enrollment":214},{"nctId":"NCT04914741","phase":"PHASE1, PHASE2","title":"A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-06-29","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":80},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT03902665","phase":"PHASE2","title":"Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-03-15","conditions":"Acute Myeloid Leukemia, Adult","enrollment":19},{"nctId":"NCT04933617","phase":"PHASE1","title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-24","conditions":"Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma","enrollment":8},{"nctId":"NCT06451302","phase":"NA","title":"Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yizhuo Zhang","startDate":"2024-04-17","conditions":"Ewing Sarcoma, Risk Stratification","enrollment":100},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT00085124","phase":"PHASE3","title":"Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-12","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","enrollment":500},{"nctId":"NCT02393859","phase":"PHASE3","title":"Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-10","conditions":"Leukemia, Acute Lymphoblastic","enrollment":111},{"nctId":"NCT04526288","phase":"PHASE2","title":"CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-08-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm","enrollment":1},{"nctId":"NCT03017326","phase":"PHASE3","title":"Paediatric Hepatic International Tumour Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2017-08-24","conditions":"Hepatoblastoma, Carcinoma, Hepatocellular","enrollment":450},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"High-dose anthracycline","genericName":"High-dose anthracycline","companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose anthracycline, specifically Doxorubicin, is used to treat various conditions including High-Risk Localized Soft Tissue Sarcoma, Breast Cancer, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, and Hormone Receptor Positive HER-2 Negative Breast Cancer. It is a small molecule modality that works through an unknown mechanism, but is often administered in combination with other treatments such as radiotherapy and immunotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}